Literature DB >> 10706970

Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1.

G A Pietersz1, W Li, C Osinski, V Apostolopoulos, I F McKenzie.   

Abstract

Mucin1 (MUC1) is expressed ubiquitously on breast cancer cells and is a potential target for the generation of cytotoxic T cells for vaccination against breast cancer. Thus far studies of the immunogenicity of MUC1 have used peptides from the variable number of tandem repeat (VNTR); mice so immunised can generate strong cellular and antibody responses to the VNTR of human MUC1. We now demonstrate that significant CTL and CTLp can be induced to other regions of MUC1. Using the whole native MUC1 molecule, the human milk fat globule membrane antigen (HMFG) linked to mannan, cytotoxic T cell precursors (CTLp) can be generated in BALB/c, C57BL/6, transgenic HLA-A*0201/K(b) and double transgenic HLA-A*0201/K(b)xhuman MUC1 (A2 K(b)MUC1) mice. By immunising with HMFG and testing selectively on (a) extracellular (non-VNTR); (b) VNTR and (c) intracellular peptides, it was shown that all three regions generated effective CTL. Further, the CTL responses to non-VNTR peptides were as strong as those generated to the VNTR. Epitope prediction algorithms were not particularly helpful to describe CTL epitopes: overlapping peptides had to be synthesised and tested to find the epitopes. Thus, for CTL generation, the whole HMFG molecule is a powerful immunogen when linked to mannan, especially as multiple peptide epitopes for presentation by many Class I molecules are contained within the one molecule. Furthermore, Class I restricted MUC1 CTL were generated in double transgenic A2 K(b)MUC1 mice by immunising with mannan-native mucin (HMFG), suggesting that tolerance to MUC1 can be overcome with mannan-HMFG.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10706970     DOI: 10.1016/s0264-410x(99)00515-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  The Tat-conjugated N-terminal region of mucin antigen 1 (MUC1) induces protective immunity against MUC1-expressing tumours.

Authors:  H Yang; N-H Cho; S-Y Seong
Journal:  Clin Exp Immunol       Date:  2009-07-17       Impact factor: 4.330

Review 2.  MUC1 in carcinoma-host interactions.

Authors:  K Denda-Nagai; T Irimura
Journal:  Glycoconj J       Date:  2000 Jul-Sep       Impact factor: 3.009

Review 3.  MUC1, the renaissance molecule.

Authors:  S J Gendler
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-07       Impact factor: 2.698

4.  Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835].

Authors:  Vasso Apostolopoulos; Geoffrey A Pietersz; Anastasios Tsibanis; Annivas Tsikkinis; Heleni Drakaki; Bruce E Loveland; Sara J Piddlesden; Magdalena Plebanski; Dodie S Pouniotis; Michael N Alexis; Ian F McKenzie; Stamatis Vassilaros
Journal:  Breast Cancer Res       Date:  2006-06-15       Impact factor: 6.466

5.  Mannan adjuvants intranasally administered inactivated influenza virus in mice rendering low doses inductive of strong serum IgG and IgA in the lung.

Authors:  Owen Proudfoot; Sandra Esparon; Choon-Kit Tang; Karen Laurie; Ian Barr; Geoffrey Pietersz
Journal:  BMC Infect Dis       Date:  2015-02-26       Impact factor: 3.090

6.  Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.

Authors:  Caroline B Madsen; Cecilie Petersen; Kirstine Lavrsen; Mikkel Harndahl; Søren Buus; Henrik Clausen; Anders E Pedersen; Hans H Wandall
Journal:  PLoS One       Date:  2012-11-26       Impact factor: 3.240

7.  An anti-MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells.

Authors:  C Heuser; M Ganser; A Hombach; H Brand; G Denton; F-G Hanisch; H Abken
Journal:  Br J Cancer       Date:  2003-09-15       Impact factor: 7.640

8.  Mucin immunohistochemistry in the diagnosis and mapping of extramammary Paget's disease.

Authors:  R F Smith; B H Stern; A A Smith
Journal:  J Cell Mol Med       Date:  2007-12-10       Impact factor: 5.310

9.  Immunogenicity of chimeric MUC1-HER2 vaccine against breast cancer in mice.

Authors:  Elaheh Gheybi; Ali Hatef Salmanian; Abbas Ali Imani Fooladi; Jafar Salimian; Hamideh Mahmoodzadeh Hosseini; Raheleh Halabian; Jafar Amani
Journal:  Iran J Basic Med Sci       Date:  2018-01       Impact factor: 2.699

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.